Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis

Table 1 The general characteristic of the included studies

Author	Participant (E/C)	Mean age (year, E/C)	Male/female(%, E/C)	Intervention	Control	Outcomes	Follow-up	Study
Kinov 2005	12/12	NS	NS	35 mg risedronate	Placebo	1, 2, 8	6 months	RCTs
Yamasaki 2007	19/21	66.8/66.6	23.2/23.9	2.5 mg/day orally	Placebo	1, 2, 3, 4, 5	6 months	RCTs
Skoldenberg 2011	36/37	61/60	55/55	35 mg risedronate	Placebo	1, 2, 3, 4, 6, 7, 8	12 months	RCTs
Kumar 2011	30/31	60/61	59/61	35 mg risedronate	Placebo	1, 2, 3, 4, 5, 6, 7, 8	1 years	RCTs
Muren 2015	30/31	62/60	52/54	35 mg risedronate	Placebo	1, 2, 3, 4, 5, 6, 7, 8	4 years	RCTs

E, risedronate group; C, control group; RCT, randomized controlled trials; 1, BMD change in zone 1; 2, BMD change in zone 7; 3, BMD change in zone 2; 4, BMD change in zone 3; 5, BMD change in zone 4; 6, BMD change in zone 5; 7, BMD change in zone 6; 8, Harris hip scores

ISSN: 1749-799X